drugset / Trial / NCT00821535

Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers

NCT00821535

Phase 1 Completed 12 enrolled ViiV Healthcare Pfizer · collab
NaSingle-groupOpen-label

Summary

To confirm safety and pharmacokinetics of maraviroc following a single oral dose of 300 mg maraviroc in healthy male Japanese volunteers.

Timeline

Start
2009-02
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Maraviroc Other / unclassified 300 mg Oral